The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study

Laura Delgado-Ortega (), Almudena González-Domínguez (), Josep María Borrás (), Juan Oliva (), Eva González-Haba (), Salomón Menjón (), Pedro Pérez (), David Vicente (), Luis Cordero (), Margarita Jiménez (), Susana Simón (), Álvaro Hidalgo-Vega () and Carlota Moya-Alarcón ()
Additional contact information
Laura Delgado-Ortega: AstraZeneca Farmacéutica Spain
Almudena González-Domínguez: Weber
Josep María Borrás: University of Barcelona
Eva González-Haba: Hospital General Universitario Gregorio Marañón
Salomón Menjón: Hospital Universitario Virgen de las Nieves
Pedro Pérez: Hospital Clínico Universitario
David Vicente: Hospital Universitario Virgen Macarena
Luis Cordero: AstraZeneca Farmacéutica Spain
Margarita Jiménez: Weber
Susana Simón: AstraZeneca Farmacéutica Spain
Álvaro Hidalgo-Vega: Universidad de Castilla-La Mancha – Campus de Toledo
Carlota Moya-Alarcón: AstraZeneca Farmacéutica Spain

The European Journal of Health Economics, 2019, vol. 20, issue 1, No 10, 135-147

Abstract: Abstract Objective To assess the economic burden of epithelial ovarian cancer (EOC) in incident patients and the burden by disease stage in Spain. Methods We developed a Markov model from a social perspective simulating the natural history of EOC and its four stages, with a 10-year time horizon, 3-week cycles, 3% discount rate, and 2016 euros. Healthcare resource utilization and costs were estimated by disease stage. Direct healthcare costs (DHC) included early screening, genetic counselling, medical visits, diagnostic tests, surgery, chemotherapy, hospitalizations, emergency services, and palliative care. Direct non-healthcare costs (DNHC) included formal and informal care. Indirect costs (IC) included labour productivity losses due to temporary and permanent leaves, and premature death. Epidemiology data and resource use were taken from the literature and validated for Spain by the OvarCost group using a Delphi method. Results The total burden of EOC over 10 years was 3102 mill euros: 15.1% in stage I, 3.9% in stage II, 41.0% in stage III, and 40.2% in stage IV. Annual average cost/patient was €24,111 and it was €8,641; €14,184; €33,858, and €42,547 in stages I–IV, respectively. Of total costs, 71.2% were due to DHC, 24.7% to DNHC, and 4.1% to IC. Conclusions EOC imposes a significant economic burden on the national healthcare system and society in Spain. Investment in better early diagnosis techniques might increase survival and patients’ quality of life. This would likely reduce costs derived from late stages, consequently leading to a substantial reduction of the economic burden associated with EOC.

Keywords: Epithelial ovarian cancer; Economic burden of disease; Healthcare resource utilization; Spain (search for similar items in EconPapers)
Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://link.springer.com/10.1007/s10198-018-0986-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:20:y:2019:i:1:d:10.1007_s10198-018-0986-y

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-018-0986-y

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().